MXPA04004900A - Uso de propionil-l-carnitina o una de sus sales farmacologicamente aceptables para la preparacion de un medicamento para el tratamiento de la enfermedad de la peyronie. - Google Patents
Uso de propionil-l-carnitina o una de sus sales farmacologicamente aceptables para la preparacion de un medicamento para el tratamiento de la enfermedad de la peyronie.Info
- Publication number
- MXPA04004900A MXPA04004900A MXPA04004900A MXPA04004900A MXPA04004900A MX PA04004900 A MXPA04004900 A MX PA04004900A MX PA04004900 A MXPA04004900 A MX PA04004900A MX PA04004900 A MXPA04004900 A MX PA04004900A MX PA04004900 A MXPA04004900 A MX PA04004900A
- Authority
- MX
- Mexico
- Prior art keywords
- carnitine
- propionyl
- peyronie
- disease
- treatment
- Prior art date
Links
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title abstract 7
- 208000004362 Penile Induration Diseases 0.000 title abstract 5
- 208000020758 Peyronie disease Diseases 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 abstract 2
- 238000011443 conventional therapy Methods 0.000 abstract 2
- 238000007918 intramuscular administration Methods 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 2
- 229960001722 verapamil Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invencion que aqui se describe se refiere al uso de propionil-L-carnitina o una de sus sales farmaceuticamente aceptables para la preparacion de un medicamento util para el tratamiento de la enfermedad de La Peyronie en sus diversas etapas, particularmente en la etapa avanzada y en formas resistentes a terapias convencionales. El medicamento es adecuado para administracion oral, intramuscular, intravenosa e intraplaca. La invencion que aqui se describe tambien se refiere a una combinacion de un ingrediente activo en el tratamiento de la enfermedad de La Peyronie, particularmente verapamilo, y propionil-L-carnitina o una de sus sales farmaceuticamente aceptables. La propionil-L-carnitina ha probado ser mas efectiva que los ingredientes activos conocidos, tambien en formas intratables, y presenta una incidencia mas baja de efectos secundarios.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000695A ITRM20010695A1 (it) | 2001-11-26 | 2001-11-26 | Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del |
| PCT/IT2002/000745 WO2003045373A1 (en) | 2001-11-26 | 2002-11-26 | Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04004900A true MXPA04004900A (es) | 2004-08-02 |
Family
ID=11455896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04004900A MXPA04004900A (es) | 2001-11-26 | 2002-11-26 | Uso de propionil-l-carnitina o una de sus sales farmacologicamente aceptables para la preparacion de un medicamento para el tratamiento de la enfermedad de la peyronie. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050038044A1 (es) |
| EP (1) | EP1448184B1 (es) |
| JP (1) | JP4370168B2 (es) |
| KR (1) | KR100923139B1 (es) |
| AT (1) | ATE323481T1 (es) |
| AU (1) | AU2002358991A1 (es) |
| CA (1) | CA2466135C (es) |
| CY (1) | CY1105347T1 (es) |
| DE (1) | DE60210804T2 (es) |
| DK (1) | DK1448184T3 (es) |
| ES (1) | ES2261772T3 (es) |
| HU (1) | HUP0402118A3 (es) |
| IT (1) | ITRM20010695A1 (es) |
| MX (1) | MXPA04004900A (es) |
| PL (1) | PL209317B1 (es) |
| PT (1) | PT1448184E (es) |
| WO (1) | WO2003045373A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2658307C2 (de) * | 1976-12-22 | 1979-03-15 | Klinge Pharma Gmbh & Co, 8000 Muenchen | Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AU556001B2 (en) * | 1981-11-18 | 1986-10-16 | Unilever Plc | Fat refining |
| US5038633A (en) * | 1989-09-28 | 1991-08-13 | Kabushiki Kaisha Kobe Seiko Sho | Transmission for mini shovel car |
| IT1283967B1 (it) * | 1996-03-29 | 1998-05-07 | Sigma Tau Ind Farmaceuti | Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi |
| US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
| IT1290600B1 (it) * | 1997-04-30 | 1998-12-10 | Sigma Tau Ind Farmaceuti | Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato |
| IT1302858B1 (it) * | 1998-11-11 | 2000-10-10 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale. |
-
2001
- 2001-11-26 IT IT2001RM000695A patent/ITRM20010695A1/it unknown
-
2002
- 2002-11-26 EP EP02793337A patent/EP1448184B1/en not_active Expired - Lifetime
- 2002-11-26 DK DK02793337T patent/DK1448184T3/da active
- 2002-11-26 HU HU0402118A patent/HUP0402118A3/hu unknown
- 2002-11-26 DE DE60210804T patent/DE60210804T2/de not_active Expired - Lifetime
- 2002-11-26 MX MXPA04004900A patent/MXPA04004900A/es active IP Right Grant
- 2002-11-26 WO PCT/IT2002/000745 patent/WO2003045373A1/en not_active Ceased
- 2002-11-26 PT PT02793337T patent/PT1448184E/pt unknown
- 2002-11-26 PL PL371012A patent/PL209317B1/pl unknown
- 2002-11-26 ES ES02793337T patent/ES2261772T3/es not_active Expired - Lifetime
- 2002-11-26 KR KR1020047007881A patent/KR100923139B1/ko not_active Expired - Fee Related
- 2002-11-26 AU AU2002358991A patent/AU2002358991A1/en not_active Abandoned
- 2002-11-26 CA CA2466135A patent/CA2466135C/en not_active Expired - Fee Related
- 2002-11-26 US US10/496,659 patent/US20050038044A1/en not_active Abandoned
- 2002-11-26 AT AT02793337T patent/ATE323481T1/de active
- 2002-11-26 JP JP2003546875A patent/JP4370168B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-30 CY CY20061100685T patent/CY1105347T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002358991A1 (en) | 2003-06-10 |
| HUP0402118A3 (en) | 2012-09-28 |
| EP1448184A1 (en) | 2004-08-25 |
| ITRM20010695A1 (it) | 2003-05-26 |
| EP1448184B1 (en) | 2006-04-19 |
| JP4370168B2 (ja) | 2009-11-25 |
| KR20040058316A (ko) | 2004-07-03 |
| KR100923139B1 (ko) | 2009-10-23 |
| PL371012A1 (en) | 2005-06-13 |
| ES2261772T3 (es) | 2006-11-16 |
| JP2005511638A (ja) | 2005-04-28 |
| HUP0402118A2 (hu) | 2005-02-28 |
| CA2466135C (en) | 2011-05-31 |
| WO2003045373A1 (en) | 2003-06-05 |
| ATE323481T1 (de) | 2006-05-15 |
| DE60210804T2 (de) | 2006-10-19 |
| PL209317B1 (pl) | 2011-08-31 |
| DE60210804D1 (de) | 2006-05-24 |
| CA2466135A1 (en) | 2003-06-05 |
| PT1448184E (pt) | 2006-07-31 |
| ITRM20010695A0 (it) | 2001-11-26 |
| US20050038044A1 (en) | 2005-02-17 |
| DK1448184T3 (da) | 2006-08-21 |
| CY1105347T1 (el) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| CA2401569A1 (en) | Low dose entecavir formulation and use | |
| BG106251A (en) | Levodopa (carbidopa) entacapone pharmaceutical preparation | |
| DE69829175D1 (de) | Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| EP1426375A3 (en) | Analgesic spiroindole derivatives | |
| CA2004239A1 (en) | Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment | |
| NO306894B1 (no) | Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet | |
| WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| JP2002528502A5 (es) | ||
| EP2138175A3 (en) | Formulations comprising valsartan for treating diabetes or microalbuminuria | |
| WO2004050025A3 (en) | Combination of ibuprofen and oxycodone for acute pain relief | |
| DE69928806D1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| AU2173101A (en) | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | |
| PL371012A1 (en) | Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| GEP20053512B (en) | S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders. | |
| CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
| WO2001028541A3 (en) | Composition comprising sildenafil and l-arginine | |
| EP1623709A4 (en) | REMEDY FOR RHEUMATOID ARTHRITIS | |
| MD1610F1 (en) | Method of the recidivating chronic aphthous stomatitis treatment | |
| CO5160246A1 (es) | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias | |
| WO1999048483A8 (en) | (-)-phenylpropanolamine as a sympathomimetic drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |